Home › Companies › Tarsus Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Tarsus Pharmaceuticals, Inc.’s Form 8-K, filed June 29, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 25, 2026: 6 items on Tarsus Pharmaceuticals, Inc.’s Form 8-K, filed June 29, 2026: 4 elected · 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Tarsus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Tarsus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Wendy Yarno, MBA | 34,398,690 | -- | -- | 374,956 | 3,463,568 | 99% | Elected | — |
| Elect Director: Andrew Goldberg, M.D. | 26,733,789 | -- | -- | 8,039,857 | 3,463,568 | 77% | Elected | — |
| Elect Director: Scott Morrison | 34,225,471 | -- | -- | 548,175 | 3,463,568 | 98% | Elected | — |
| Elect Director: David E.I. Pyott, MBA | 33,612,963 | -- | -- | 1,160,683 | 3,463,568 | 97% | Elected | — |
| The following directors, in addition to Ms. Yarno, Dr. | 34,486,767 | 238,014 | 48,865 | -- | 3,463,568 | 99.3% | Approved | — |
| 3. Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm | 38,219,521 | 3,651 | 14,042 | -- | -- | 99.9% | Approved | — |
Source: Tarsus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 29, 2026 — read the filing on EDGAR.
Each item below shows how the 289 asset managers that disclosed a Tarsus Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Tarsus Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Andrew Goldberg
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Andrew Goldberg, M.D.”): 26,733,789 for, 8,039,857 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 9,333,289 for, 2,236,585 withheld, 17 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,084,408 | 0 | 17 | 23,250 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,286,608 | 0 | 0 | 18,000 | For |
| Prudential/PGIM | 667,367 | 0 | 0 | 98,272 | Mixed |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 0 | 0 | 273,131 | Withhold |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 261,461 | Withhold |
| Loomis Sayles | 0 | 0 | 0 | 222,303 | Withhold |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 174,580 | Withhold |
| Putnam | 147,318 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 120,498 | Withhold |
| Equitable | 91,148 | 0 | 0 | 25,540 | Mixed |
| First Trust | 0 | 0 | 0 | 110,377 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 100,000 | Withhold |
| State Street | 97,305 | 0 | 0 | 65 | For |
| Bridge Builder Trust | 34,384 | 0 | 0 | 55,134 | Mixed |
| MoA Funds Corp | 0 | 0 | 0 | 67,022 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 62,395 | Withhold |
Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: David E.I. Pyott
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David E.I. Pyott, MBA”): 33,612,963 for, 1,160,683 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 10,693,047 for, 876,840 withheld, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,107,672 | 0 | 3 | 0 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,304,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 765,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 0 | 0 | 273,131 | Withhold |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 261,461 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 0 | 0 | 222,303 | Withhold |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 174,580 | 0 | 0 | 0 | For |
| Putnam | 10,117 | 0 | 0 | 137,201 | Mixed |
| Allspring | 120,498 | 0 | 0 | 0 | For |
| Equitable | 116,688 | 0 | 0 | 0 | For |
| First Trust | 110,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 100,000 | Withhold |
| State Street | 97,370 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 89,518 | 0 | 0 | 0 | For |
| MoA Funds Corp | 67,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
| Brighthouse | 12,660 | 0 | 0 | 49,735 | Mixed |
Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Scott Morrison
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Scott Morrison”): 34,225,471 for, 548,175 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 11,557,159 for, 12,730 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,105,824 | 0 | 1 | 1,850 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,304,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 765,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 273,131 | 0 | 0 | 0 | For |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 261,461 | 0 | 0 | 0 | For |
| Loomis Sayles | 222,303 | 0 | 0 | 0 | For |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 174,580 | 0 | 0 | 0 | For |
| Putnam | 147,318 | 0 | 0 | 0 | For |
| Allspring | 120,498 | 0 | 0 | 0 | For |
| Equitable | 116,688 | 0 | 0 | 0 | For |
| First Trust | 110,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 100,000 | 0 | 0 | 0 | For |
| State Street | 97,370 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 89,518 | 0 | 0 | 0 | For |
| MoA Funds Corp | 67,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
| Brighthouse | 59,141 | 0 | 0 | 3,254 | Mixed |
Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Wendy Yarno
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Wendy Yarno, MBA”): 34,398,690 for, 374,956 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 11,566,635 for, 3,254 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,107,674 | 0 | 1 | 0 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,304,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 765,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 273,131 | 0 | 0 | 0 | For |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 261,461 | 0 | 0 | 0 | For |
| Loomis Sayles | 222,303 | 0 | 0 | 0 | For |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 174,580 | 0 | 0 | 0 | For |
| Putnam | 147,318 | 0 | 0 | 0 | For |
| Allspring | 120,498 | 0 | 0 | 0 | For |
| Equitable | 116,688 | 0 | 0 | 0 | For |
| First Trust | 110,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 100,000 | 0 | 0 | 0 | For |
| State Street | 97,370 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 89,518 | 0 | 0 | 0 | For |
| MoA Funds Corp | 67,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
| Brighthouse | 59,141 | 0 | 0 | 3,254 | Mixed |
Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.6% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,107,674 | 0 | 0 | 0 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,304,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 765,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 273,131 | 0 | 0 | 0 | For |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 261,461 | 0 | 0 | 0 | For |
| Loomis Sayles | 222,303 | 0 | 0 | 0 | For |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 174,580 | 0 | 0 | 0 | For |
| Putnam | 147,318 | 0 | 0 | 0 | For |
| Allspring | 120,498 | 0 | 0 | 0 | For |
| Equitable | 116,688 | 0 | 0 | 0 | For |
| First Trust | 110,377 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 100,981 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 100,000 | 0 | 0 | 0 | For |
| State Street | 97,370 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 89,518 | 0 | 0 | 0 | For |
| MoA Funds Corp | 67,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
Fund voting reports, all 86 managers: 11,609,988 for, 3,272 against, 33,254 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 4,604,707 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 3,557,678 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 3,346,025 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 2,002,080 | 0 | 0 | 0 | For |
| Invesco | 1,666,003 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 1,399,098 | 0 | 0 | 0 | For |
| BlackRock | 1,374,163 | 195 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,025,721 | 0 | 0 | 0 | For |
| State Street | 881,939 | 1,255 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 728,644 | 0 | 0 | 0 | For |
| Fidelity | 703,822 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 685,216 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 543,961 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 499,306 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 493,320 | 0 | 0 | 0 | For |
| Loomis Sayles | 393,994 | 0 | 0 | 0 | For |
| TimesSquare Capital Management, LLC | 356,340 | 0 | 0 | 0 | For |
| Charles Schwab | 329,603 | 0 | 0 | 0 | For |
| Northern Trust | 324,895 | 0 | 0 | 0 | For |
| Vanguard | 318,838 | 0 | 0 | 0 | For |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 316,595 | 0 | 0 | 0 | For |
| T. Rowe Price | 308,687 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 307,504 | 0 | 0 | 0 | For |
| Nuveen | 283,246 | 0 | 0 | 0 | For |
| Artisan | 264,197 | 0 | 0 | 0 | For |
Institutional-manager reports, all 232 managers: 30,698,371 for, 124,712 against, 24,951 abstained, 180 not voted. Showing the 25 largest; see all in the interactive database.
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Tarsus Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm”): 38,219,521 for, 3,651 against — passed, per its Form 8-K filed June 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm The Company's stockholders approved the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 11,566,636 for, 3,254 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,107,675 | 0 | 0 | 0 | For |
| BlackRock | 1,588,579 | 0 | 0 | 0 | For |
| Fidelity | 1,304,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 765,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 738,221 | 0 | 0 | 0 | For |
| Lord Abbett | 504,366 | 0 | 0 | 0 | For |
| Legg Mason | 443,209 | 0 | 0 | 0 | For |
| Invesco | 441,422 | 0 | 0 | 0 | For |
| Charles Schwab | 329,520 | 0 | 0 | 0 | For |
| Waddell & Reed | 273,131 | 0 | 0 | 0 | For |
| TIAA | 267,608 | 0 | 0 | 0 | For |
| MFS | 261,461 | 0 | 0 | 0 | For |
| Loomis Sayles | 222,303 | 0 | 0 | 0 | For |
| T. Rowe Price | 180,401 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 174,580 | 0 | 0 | 0 | For |
| Putnam | 147,318 | 0 | 0 | 0 | For |
| Allspring | 120,498 | 0 | 0 | 0 | For |
| Equitable | 116,688 | 0 | 0 | 0 | For |
| First Trust | 110,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 100,000 | 0 | 0 | 0 | For |
| State Street | 97,370 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 89,518 | 0 | 0 | 0 | For |
| MoA Funds Corp | 67,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 64,885 | 0 | 0 | 0 | For |
| Brighthouse | 59,141 | 0 | 3,254 | 0 | Mixed |
Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 43,021,312 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.90% |
| 2 | BlackRock | 3.69% |
| 3 | Fidelity | 3.03% |
| 4 | Prudential/PGIM | 1.78% |
| 5 | JANUS INVESTMENT FUND | 1.72% |
| 6 | Lord Abbett | 1.17% |
| 7 | Legg Mason | 1.03% |
| 8 | Invesco | 1.03% |
| 9 | Charles Schwab | 0.77% |
| 10 | Waddell & Reed | 0.63% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 10.70% |
| 2 | Deep Track Capital, LP | 8.27% |
| 3 | RTW INVESTMENTS, LP | 7.78% |
| 4 | Paradigm Biocapital Advisors LP | 4.65% |
| 5 | Invesco | 3.87% |
| 6 | JENNISON ASSOCIATES LLC | 3.25% |
| 7 | BlackRock | 3.19% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.38% |
| 9 | State Street | 2.05% |
| 10 | Frazier Life Sciences Management, L.P. | 1.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Deep Track Capital, LP | 8.37% | 13G |
| BlackRock | 8.26% | 13F |
| RTW Investments, LP | 7.96% | DEF14A |
| Paradigm BioCapital Advisors LP | 5.67% | DEF14A |
| Vanguard Group | 5.58% | 13F |
| JANUS HENDERSON GROUP PLC | 5.21% | 13G |
| Bobak Azamian | 5.16% | DEF14A |
| Morgan Stanley | 4.74% | 13F |
| PRUDENTIAL FINANCIAL INC | 4.27% | 13G |
| Jennison Associates LLC | 3.98% | 13G |
Percentages above are of 43,021,312 shares outstanding, as reported by Tarsus Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Tarsus Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Tarsus Pharmaceuticals, Inc.'s shareholder meeting held June 25, 2026, in the 2025-2026 proxy season, 289 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,850 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Tarsus Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To hold an advisory vote to approve, on a non-binding basis, our named executive officer… — the reporting funds and managers cast 99.6% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
Tarsus Pharmaceuticals, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.